Telios Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Telios Pharma sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Telios Pharma: 8 sponsored US clinical trials, 4 recruiting.
Telios Pharma sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 2 trials.
Upper-quartile sponsor footprint
Telios Pharma sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
NCT07220408
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
NCT06686472
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
NCT04655118
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
NCT06225973
A Study Of TL-925 For The Treatment of AC
NCT06293820
A Study of TL-925 as a Treatment for Dry Eye Disease
NCT05745064
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
NCT04419623
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
Therapeutic Areas
What is open in the Telios Pharma pipeline
4 recruiting of 8 indexed (50% open); 3 completed (38%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Dry Eye Disease (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Telios Pharma: open-pipeline peers nationwide
Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Telios Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Telios Pharma page
8 registered trials is a research-attention snapshot, not an endorsement of Telios Pharma or any single study.
- 4 of Telios Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dry Eye Disease is the condition Telios Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Telios Pharma pipeline card: 8 registered trials from official public datasets.Report a data error.